(Q38262435)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25342235%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

review article

1 reference

title

Pharmacological treatment and therapeutic perspectives of metabolic syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25342235%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25342235%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Robert H Eckel

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25342235%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

1 December 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25342235%20AND%20SRC:MED&resulttype=core&format=json

Reviews in Endocrine and Metabolic Disorders

21 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25342235%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25342235%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25342235%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

329-341

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25342235%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11154-014-9298-4

21 February 2020

exact match

0 references

cites work

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

The metabolic syndrome--a new worldwide definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Inflammation: the link between insulin resistance, obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

The metabolic syndrome and aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Prospective analysis of the insulin-resistance syndrome (syndrome X).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Etiology of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

The key role of insulin resistance in the cardiometabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Influence of body fat distribution on free fatty acid metabolism in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Links between ectopic fat and vascular disease in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Mechanisms linking obesity with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Serum uric acid is a determinant of metabolic syndrome in a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Dyslipidemia of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Low-grade inflammation, and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

The renin-angiotensin system in adipose tissue and its metabolic consequences during obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Lifestyle modification for metabolic syndrome: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Pioglitazone for diabetes prevention in impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

The treatment of cardiovascular disease continuum: focus on prevention and RAS blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Multicenter, placebo-controlled trial of lorcaserin for weight management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

The insulin sensitizing effect of topiramate involves KATP channel activation in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

The many faces of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Mechanisms underlying current and future anti-obesity drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Lorcaserin: A novel antiobesity drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Phentermine/topiramate for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

In vivo and in vitro studies of a functional peroxisome proliferator-activated receptor gamma response element in the mouse pdx-1 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Molecular regulation of pancreatic beta-cell mass development, maintenance, and expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Homeodomain protein IDX-1: a master regulator of pancreas development and insulin gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Thiazolidinediones improve beta-cell function in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

21 January 2018

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Use of thiazolidinediones and fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Lymphocyte-suppressing and systemic anti-inflammatory effects of high-dose metformin in simvastatin-treated patients with impaired fasting glucose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Regulation of the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Human cholesterol metabolism and therapeutic molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Statin for the primary prevention of cardiovascular disease in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Beyond lipid lowering: the role of statins in vascular protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Different time trends of caloric and fat intake between statin users and nonusers among US adults: gluttony in the time of statins?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Fenofibrate improves endothelial function and decreases thrombin-activatable fibrinolysis inhibitor concentration in metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Inhibition of the renin-angiotensin system prevents free fatty acid-induced acute endothelial dysfunction in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

The role of the renin-angiotensin system in the development of insulin resistance in skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Role of Angiotensin II AT1 Receptor Blockers in the Treatment of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Tyrosine kinases in activation of the MAP kinase cascade by G-protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Angiotensin converting enzyme inhibitors for prevention of new-onset type 2 diabetes mellitus: a meta-analysis of 72,128 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Molecular-specific effects of angiotensin II antagonists: clinical relevance to treating hypertension?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Angiotensin-converting enzyme (ACE) inhibitors modulate cellular retinol-binding protein 1 and adiponectin expression in adipocytes via the ACE-dependent signaling cascade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Anti-oxidative properties of beta-blockers and angiotensin-converting enzyme inhibitors in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

The potential anti-inflammatory benefits of improving physical fitness in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

The role of irbesartan in the treatment of patients with hypertension: a comprehensive and practical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Effect of Renin-Angiotensin system inhibition on cardiovascular events in older hypertensive patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Anti-inflammatory role of cilostazol in vascular smooth muscle cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Elevated Lp-PLA 2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9298-4

Cardiovascular morbidity and mortality associated with the metabolic syndrome

21 January 2018

1 reference

12 December 2020

Independent prediction of metabolic syndrome by plasma fibrinogen in men, and predictors of elevated levels

1 reference

12 December 2020

Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia

1 reference

12 December 2020

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction

1 reference

12 December 2020

Metabolic syndrome in Mexican adults: results from the National Health and Nutrition Survey 2006.

1 reference

12 December 2020

Activation of a cAMP-regulated Ca(2+)-signaling pathway in pancreatic beta-cells by the insulinotropic hormone glucagon-like peptide-1

1 reference

12 December 2020

Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.

1 reference

12 December 2020

Metabolic syndrome: recent prevalence in East and Southeast Asian populations.

1 reference

12 December 2020

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

1 reference

12 December 2020

GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress

1 reference

12 December 2020

Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats

1 reference

12 December 2020

Hepatic failure in a patient taking rosiglitazone

1 reference

12 December 2020

American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC

1 reference

12 December 2020

s-ICAM-1 and s-VCAM-1 in healthy men are strongly associated with traits of the metabolic syndrome, becoming evident in the postprandial response to a lipid-rich meal.

1 reference

12 December 2020

Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation

1 reference

12 December 2020

Atherosclerosis, inflammation, leukocyte function and the effect of statins

1 reference

12 December 2020

Do we need anti-obesity drugs?

1 reference

12 December 2020

Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence

1 reference

12 December 2020

Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss

1 reference

12 December 2020

10.1007/S11154-014-9298-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25342235%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

21 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25342235%20AND%20SRC:MED&resulttype=core&format=json